Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration

Podobne zapisy

• Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies
  od: Agrawal, Sudhir, i wsp.
  Wydane: (1997)
• Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
  od: Wang, Hui, i wsp.
  Wydane: (2002)
• Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
  od: Tortora, Giampaolo, i wsp.
  Wydane: (1997)
• Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments.
  od: Kandimalla, E R, i wsp.
  Wydane: (1997)
• Pharmacokinetics of antisense oligonucleotide drugs
  od: M. R. Khaitov, i wsp.
  Wydane: (2013-04-01)